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Insufficient vascularization currently limits the size and complexity for all tissue engineering 
approaches. Additionally, increasing or re-initiating blood flow is the first step toward 
restoration of ischemic tissue homeostasis. However, no FDA-approved pro-angiogenic 
treatments exist, despite the many pre-clinical approaches that have been developed. 
The relatively small size of peptides gives advantages over protein-based treatments, 
specifically with respect to synthesis and stability. While many pro-angiogenic peptides 
have been identified and shown promising results in vitro and in vivo, the majority of 
biomaterials developed for pro-angiogenic drug delivery focus on protein delivery. This 
narrow focus limits pro-angiogenic therapeutics as peptides, similar to proteins, suffer 
from poor pharmacokinetics in vivo, necessitating the development of controlled release 
systems. This review discusses pro-angiogenic peptides and the biomaterials delivery 
systems that have been developed, or that could easily be adapted for peptide delivery, 
with a particular focus on depot-based delivery systems.
Keywords: angiogenesis, controlled release, biomaterials, drug delivery, hydrogels, depot-based, review
introduction
Therapeutic angiogenesis holds great potential for supporting developing engineered tissues, where 
insufficient vascularization limits size and complexity. Additionally, a number of ischemic tissue 
disorders would benefit from pro-angiogenic therapies by restoring blood flow to the tissue. However, 
no FDA-approved treatments exist to reproducibly enhance vascularization (Muir, 2009; Zachary and 
Morgan, 2011; Chu and Wang, 2012).
The field of tissue engineering has made remarkable progress in developing tissues to restore, 
augment, or replace the function of damaged tissues within the body. For example, engineered urethras 
remained functional for 6 years (Raya-Rivera et al., 2011). Similarly, tissue-engineered bladders (Atala 
et al., 2006) and trachea (Macchiarini et al., 2008) have been successfully implanted in humans, and 
remained functional at 46- and 4-month follow up exams, respectively. However, the success of 
engineered tissues has been limited to thin tissues, with engineering larger, more complex structures 
slowed by challenges associated with development of necessary vascularization to sustain growing/
remodeling tissues (Atala, 2004).
$500 billion is spent each year in the United States to treat cardiovascular diseases, such as peripheral 
arterial and coronary heart disease (Go et al., 2014). Peripheral arterial disease affects 8.5 million 
Americans, and coronary heart disease is the leading cause of death in the United States, responsible 
for ~1 in every 6 deaths in 2010 (Go et al., 2014). Currently, treatment of peripheral arterial and 
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coronary heart disease focuses on maximizing function of existing 
vasculature using vasodilators and anti-clotting agents, or through 
surgical interventions, such as angioplasty, stent placement, or 
bypass grafts, rather than encouraging development of new vascu-
lature to support the tissue (Muir, 2009; Lloyd-Jones et al., 2010).
Diabetes affects 20.8 million people in the United States, with 
15% of this population also affected by diabetic foot ulcers. Diabetic 
ulcers precede 84% of diabetes-related lower limb amputations and 
are a cause significant morbidity, making them a significant public 
health burden (Brem and Tomic-Canic, 2007). These wounds are 
resistant to healing due in part to decreased angiogenic response 
(Galiano et al., 2004), and improvements in ulcer healing have 
been obtained with repeated topical treatment with pro-angiogenic 
growth factors. However, becaplermin (recombinant platelet-
derived growth factor, PDGF) is currently the only FDA-approved 
pro-angiogenic treatment for diabetic ulcers, and even with daily 
application, only 48% of patients exhibit complete wound closure 
over 20 weeks (Steed, 1995).
This review focuses on pro-angiogenic peptides and biomateri-
als exploited for their delivery. First, the process of angiogenesis 
including the critical factors and cell types involved in this process 
is briefly reviewed. The relative merits of pro-angiogenic peptides 
as compared to proteins are discussed, as are particular challenges 
associated with the use of peptide drugs. While many of the bioma-
terials that have been developed for the delivery of pro-angiogenic 
factors focus on delivery of large proteins, this review focuses on 
identifying materials that can be adapted for delivery of the many 
promising pro-angiogenic peptides that have been identified, as 
well as materials designed specifically for peptide delivery. Both 
natural and synthetic biomaterials are discussed, with a focus on 
depot-based (rather than injectable or orally delivered) biomateri-
als as they present advantages for pro-angiogenic applications.
Angiogenesis
Vascularization is involved in tissue homeostasis, wound repair, 
tissue healing, and during the female reproductive cycle. In healthy 
tissue, development of new vasculature is a carefully orchestrated 
process controlled by growth factor signals. New vasculature within 
the body is formed by three processes: vasculogenesis, angiogenesis, 
and arteriogenesis (Heil et al., 2006). Vasculogenesis occurs early in 
development and gives rise to the primitive circulatory system, but 
does not occur during adulthood. Angiogenesis and arteriogenesis, 
however, frequently occur in adult tissue (Chu and Wang, 2012). 
Angiogenesis is the sprouting and growth of new, small vessels 
from existing vasculature, followed by the subsequent remodeling 
and maturation of the newly developed vasculature. Arteriogenesis 
typically occurs when larger arteries are occluded, and involves 
the remodeling of pre-existing vasculature into fully developed, 
functional arteries (Heil et al., 2006; Chu and Wang, 2012).
While arteriogenesis occurs in response to changes in shear 
stress within a vessel, angiogenesis responds to tissue hypoxia or 
insufficient tissue oxygen tension (Adams and Alitalo, 2007). This 
initiates growth factor signaling cascades that drive the forma-
tion of new vasculature toward the ischemic tissue. A schematic 
representation of this process is shown in Figure 1, which includes 
a summary of key growth factors involved in the process. First, low 
FiGURe 1 | A schematic of the process of angiogenesis. Angiogenesis is 
a process tightly controlled by a number of factors. (A) Ischemic tissue release 
pro-angiogenic signals, which diffuse into nearby tissue. (B) Pericytes detach 
from nearby vessels, and ECs form sprouts. (C) ECs proliferate and migrate 
towards the signal gradient. (D) ECs align into immature vessels. (e) Pericytes 
are recruited to the new vessels. (F) Vasculature is remodeled and stabilized. 
Many of the factors involved in this process have been exploited for 
pharmacological intervention, either supplementing them for pro-angiogenic 
applications, or inhibiting them for anti-angiogenic applications. EC, 
endothelial cell; HIF-1α, hypoxia-inducible factor-1α; VEGF, vascular 
endothelial growth factor; Ang2, angiopoietin 2; PDGF, platelet-derived growth 
factor; MMPs, matrix metalloproteinases; PLGF, placenta growth factor; 
SDF-1, stromal cell-derived factor-1; FGF, fibroblast growth factor; Ang1, 
angiopoietin 1 (Ziche et al., 2004; Hirota and Semenza, 2006; Adams and 
Alitalo, 2007; Lieu et al., 2011; Chu and Wang, 2012; Brudno et al., 2013).
oxygen tension inhibits the intracellular degradation of hypoxia 
inducible factor-1α (HIF-1α), causing HIF-1α accumulation and 
allowing it to bind with HIF-1β and activate hypoxia-responsive 
elements within target genes (Hirota and Semenza, 2006). This 
causes production of a number of angiogenic growth factors, such 
as vascular endothelial growth factor (VEGF) (Forsythe et al., 1996), 
which then diffuse into the nearby tissue (Figure 1A) (Hirota and 
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Semenza, 2006). These factors signal nearby vasculature, causing 
detachment of pericytes and sprouting of endothelial cells (ECs) 
toward the VEGF gradient (Figure  1B) (Hirota and Semenza, 
2006; Adams and Alitalo, 2007). ECs then migrate in the direc-
tion of the gradient, degrading the local extracellular matrix and 
proliferating in response to factors, such as VEGF, fibroblast growth 
factor (FGF), and stromal cell-derived factor-1 (SDF-1), produc-
ing the required number of cells for vessel formation (Figure 1C) 
(Kuhlmann et al., 2005; Adams and Alitalo, 2007; Lieu et al., 2011). 
ECs align in tube-like lumen structures, forming an immature 
vascular network (Figure  1D). Pericytes are then recruited to 
the newly formed vasculature (Figure 1E) and the pericyte–EC 
interaction is stabilized by factors, such as PDGF and Angiopoietin 
1 (Figure 1F) (Ang1) (Hirota and Semenza, 2006). A variety of 
growth factors are involved in this process as indicated in Figure 1, 
with some produced by the ischemic tissue itself and others by ECs 
and pericytes, often in response to previously expressed factors 
(Forsythe et al., 1996; Ziche et al., 2004; Kuhlmann et al., 2005; 
Hirota and Semenza, 2006; Adams and Alitalo, 2007; Lieu et al., 
2011; Chu and Wang, 2012; Brudno et al., 2013).
Dysfunctions in angiogenesis can lead to serious pathologi-
cal conditions. Excessive angiogenesis occur in diseases such as 
cancer, rheumatoid arthritis, age-related macular degeneration, 
and diabetic retinopathy, while insufficient angiogenesis is asso-
ciated with diseases like coronary arterial diseases, stroke, and 
impaired wound healing (Ziche et  al., 2004). The development 
and delivery of anti-angiogenic drugs are a large, exciting area 
of current research that has been reviewed elsewhere (Nishida 
et al., 2006; Folkman, 2007; Segal and Satchi-Fainaro, 2009; Welti 
et  al., 2013; Vasudev and Reynolds, 2014). Restoring vascular 
homeostasis holds great potential for the treatment of ischemic 
tissue diseases, and as a result, has become an area of great interest 
in the fields of drug discovery, drug delivery, and tissue engineering 
(Atala, 2004; Ziche et al., 2004; Vinoth Prabhu et al., 2011; Chu 
and Wang, 2012). In this review, we focus on biomaterials for 
the delivery of pro-angiogenic drugs, with a particular focus on 
delivery of pro-angiogenic peptides.
Pro-Angiogenic Therapies
Pro-angiogenic approaches include delivery of angiogenic proteins 
(Losordo and Dimmeler, 2004; Silva and Mooney, 2010) or gene 
therapy resulting in the expression of these proteins (Henry et al., 
2007; Gupta et al., 2009), peptide drugs (Lane et al., 1994; Finetti 
et al., 2012), a limited number of small molecule drugs (Wieghaus 
et al., 2008), as well as cell-based approaches (Rustad et al., 2012). 
However, all pro-angiogenic therapeutic strategies reaching clinical 
trials have had disappointing results (Chu and Wang, 2012). While 
the reason for failure is specific for each therapeutic approach, 
many can be attributed to the classic challenges of drug delivery: 
failure to deliver the therapeutic to the target tissue at the necessary 
doses and for the required duration, while avoiding degradation 
and delivery to off-target tissues (Bader and Putnam, 2014).
Protein Therapeutics
Pro-angiogenic approaches have largely focused on delivery 
of angiogenic proteins including but not limited to vascular 
endothelial-, fibroblast-, or platelet-derived growth factor (Losordo 
and Dimmeler, 2004; Papanas and Maltezos, 2007). Delivery of these 
factors is considered one of the more straightforward pro-angiogenic 
approaches; it is simpler and more controllable than cell- and gene-
based therapies, and many pro-angiogenic proteins are commercially 
available (Chu and Wang, 2012). However, simple injection is an 
inefficient and ineffectual delivery method, as proteins suffer from 
poor localization and rapid clearance (Laham et al., 1999). These 
drawbacks present significant challenges, as tight spatio-temporal 
control over pro-angiogenic proteins, such as VEGF, is required to 
induce formation of stable and functional vessels (Ozawa et al., 2004; 
Silva and Mooney, 2007). Additionally, as angiogenesis is a highly 
regulated process controlled by a number of growth factors, some 
work suggests that delivery of multiple pro-angiogenic proteins that 
more closely recapitulate the pro-angiogenic signaling cascade may 
be required to produce therapeutically relevant and long-lasting 
vascularization (Mooney et al., 2007; Sylven et al., 2007; Layman 
et al., 2009; Brudno et al., 2013). While many recombinant human 
proteins do not elicit a notable immune response in clinical trials, 
some have induced an immune reaction substantial enough to 
prevent their use, underlying the importance of addressing this 
possibility in translational studies (Porter, 2001).
Peptide Therapeutics
As peptides have smaller sequences than proteins (generally <50 
amino acids), peptides can be produced either synthetically or 
grown biologically in Escherichia coli or yeast, giving them more 
versatile production schemes than proteins (Lehninger et  al., 
2000). Their smaller size allows peptides to be delivered at higher 
concentrations to target tissue. Additionally, peptides often do not 
require complex tertiary structures for bioactivity (Finetti et  al., 
2012). While some pro-angiogenic peptides consist of entirely novel 
sequences (Hardy et al., 2008), many mimic the bioactive region of 
pro-angiogenic growth factors (Lane et al., 1994; Finetti et al., 2012) 
or the extracellular matrix (Demidova-Rice et al., 2011, 2012), facili-
tating rationally designed therapeutic sequences. There are many 
modifications to peptides that can be made to increase their thermal 
and protease stability, such as cyclization, substitution of amino 
acids not critical for biological effects, and use of non-natural amino 
acids (Rozek et al., 2003; Diana et al., 2008; Gentilucci et al., 2010). 
Peptide sequences have been identified that are sensitive to protease 
cleavage (West and Hubbell, 1999; Patterson and Hubbell, 2010), 
and that enhance cell penetration and uptake (Lindgren et al., 2000; 
Copolovici et al., 2014), which are attractive for use in drug delivery 
applications. Together, these many advantages make peptides an 
attractive drug class for any number of therapeutic applications.
However, there are drawbacks to the use of peptide drugs. In 
some situations, peptides do not fully retain the bioactivity of the 
parent protein and must be delivered at higher doses than protein 
counterparts to achieve similar effects (Ben-Sasson et  al., 2003). 
This is not always the case, and some peptides afford comparable 
bioactivities to the parent protein (Santulli et al., 2009). Peptides are 
still susceptible to protease degradation (Frackenpohl et al., 2001), 
and similar to proteins, peptides suffer from rapid clearance by the 
liver and kidneys, leading to poor pharmacokinetics when delivered 
systemically (Vlieghe et al., 2010; Craik et al., 2013). Peptides that 
act intracellularly may have difficulty penetrating the hydrophobic 
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cell membrane, reducing their efficacy (Copolovici et  al., 2014). 
Similar to proteins, peptides may elicit an immune response (Niman 
et al., 1983), and flexible peptide conformations can result in off-
target receptor interactions (Vlieghe et al., 2010). These drawbacks 
have likely contributed to the delayed development and approval 
of peptides as compared to small molecule and antibody-based 
therapeutics (Kaspar and Reichert, 2013). However, new synthetic 
strategies, increased interest in drugs delivered via routes beyond oral 
and parenteral routes, and the development of improved delivery 
systems have recently increased their popularity (Vlieghe et al., 2010).
This renewed interest in therapeutic peptides has resulted in the 
identification and use of peptides as pro-angiogenic therapies, as well 
as a number of other applications. In 2011, over 500 peptides were in 
pre-clinical studies, and as of 2013, there were 128 therapeutic peptides 
in the FDA-approval pipeline: 40 in phase I, 74 in Phase I/II or Phase 
II, and 14 in Phase II/III or Phase III trials. The peptides currently 
in clinical trials are designed to treat a variety of diseases, including 
cancers, acute bacterial infections, type 2 diabetes, osteoporosis, and 
chronic foot ulcers (Kaspar and Reichert, 2013; Thomas et al., 2014). 
The number of therapeutic peptides that have been identified but 
are still in pre-clinical trials is even greater, and they too encom-
pass a variety of therapeutic actions, including chemotherapeutic 
(Selivanova et al., 1997; Yang et al., 2003) and anti-inflammatory 
(Akeson et al., 1996; Schultz et al., 2005) peptides, as well as the 
pro-angiogenic peptides, which are of primary interest here (Lane 
et al., 1994; Demidova-Rice et al., 2012; Finetti et al., 2012). Select 
therapeutic peptides, their sources, and current phases of develop-
ment are listed in Table 1, and a number of pro-angiogenic peptides 
that have shown promising results are summarized in Table 2, with 
specific interesting examples further discussed here.
Qk
The potent pro-angiogenic peptide Qk was designed to mimic the 
receptor binding α-helix region of VEGF, a key factor in the early stages 
of angiogenesis (Figure 1). Based on the 17–25 amino acid region 
TABLe 1 | examples of therapeutic peptides.
Therapeutic 
application
Name Source Phase of development Reference
Wound healing DSC127 Angiotensin (1–7) Phase III Rodgers and Dizerega (2013), 
Derma Sciences (2015)
GHK Cu2+ binding region of SPARC Failed phase III trials for venous 
stasis ulcers
Pickart (2008)
Cosmetic GHK (and analogues) Cu2+ binding region of SPARC FDA-approved for both wrinkle 
treatment and hair regrowth
Pickart (2008)
Anti-inflammatory AF12198 Phage display Pre-clinical Akeson et al. (1996), Mandrup-
Poulsen (2012)
CBX129801 Cleavage product of proinsulin Phase IIb Henriksson et al. (2005), Cebix 
(2013)
Chemotherapeutic Endostatin peptide fragment I (180–199) Collagen XVIII Pre-clinical Olsson et al. (2004)
VEGF-derived peptide Exon 6a of VEGF gene Pre-clinical Lee et al. (2010)
ATN-161 Fibronectin Phase II Plunkett et al. (2002), 
Cianfrocca et al. (2006)
Osteoporosis BA058 Parathyroid hormone receptor 
(PTHR) agonist
Phase III Radius Health (2015)
Anti-bacterial Oritavancin (LY333328) Semisynthetic lipoglycopeptide 
analogue of vancomycin
FDA approved Zhanel et al. (2012), FDA 
(2014)
A selection of bioactive peptides and intended therapeutic applications.
of VEGF, Qk was strategically modified such that it would maintain 
the α-helix secondary structure of the corresponding segment of the 
full-length protein and the three-dimensional presentation of amino 
acids critical for VEGF receptor interactions. Qk is able to induce 
ERK1/2 and Akt phosphorylation similar to full-length VEGF, and 
results in similar cell proliferation and migration in vitro (D’Andrea 
et al., 2005; Diana et al., 2008; Finetti et al., 2012). While more stable 
than VEGF17–25, Qk still has a serum half-life of only ~4 h, making 
simple injection an inefficient method to maintain therapeutic levels 
of bioactive peptide (Finetti et al., 2012). As spatial and temporal con-
trol over VEGF concentration is critical for vessel formation (Mooney 
et al., 2007), it is reasonable that Qk would require similar control. 
This need for controlled delivery of this peptide is emphasized by the 
controlled release systems exploited in the in vivo studies performed 
with Qk. An infusion pump was used to deliver Qk to ischemic hind 
limbs, increasing vessel density; Matrigel and Pluronic gels have been 
used to sustain the delivery of Qk subcutaneously and to cutaneous 
wounds, increasing vessel density and the rate of wound closure, 
respectively (Santulli et al., 2009).
PAB2-1c
PAB2-1c was designed to mimic PDGF, a protein involved in 
vessel detachment and sprouting, pericyte recruitment, and vessel 
maturation and remodeling (Figure 1) (Lin et al., 2007). PAB2-1c 
was shown to bind PDGF receptors α and β and induce Akt and 
ERK1/2 phosphorylation, albeit to a lesser extent than full-length 
PDGF. Additionally, while PAB2-1c induced similar cell proliferation 
and migration, higher doses of the peptide were required to match the 
full-length protein (Lin et al., 2007). While no in vivo data have been 
published exploiting this peptide, it holds great potential for future 
applications attempting to more mimic the pro-angiogenic signaling 
cascade shown in Figure 1. For example, materials could be developed 
by delivering peptides that first stimulate the early phases of vessel 
development (i.e., the VEGF mimic Qk) followed by peptides that 
stimulate pericyte recruitment and vessel remodeling (i.e., the PDGF 
TABLe 2 | Pro-angiogenic peptides.
Pro-
angiogenic 
peptide
Sequence Source Demonstrated effects Reference
Qk KLTWQELYQLKYKGI α-helix region of VEGF Causes similar signaling and in vitro effects to full-length VEGF. 
In vivo, Qk increased vessel density in ischemic hind limbs and 
Matrigel plugs, as well as the rate of cutaneous wound closure
Santulli et al. 
(2009), Finetti 
et al. (2012)
PAB2-1c (C*VRKIEIVRKK)2–Ahx–Ahx–Ahx– 
RKRKLERIAR–NH2
Mimic of PDGF Stimulates cell proliferation, migration, and collagen gel 
contraction similar to full-length PDGF in vitro
Lin et al. 
(2007)
T7 
vasculotide
(PEG-CHHHRHSF) tetramer Tie-2-binding region of Ang1 Increases serum-free cell survival and cell migration as 
compared to controls in vitro. Increases vessel number and size 
when delivered from Matrigel, and increase the rate of diabetic 
wound closure when delivered using Intrasite Topical Gel in vivo
Van Slyke 
et al. (2009), 
Slyke (2011)
GHK, 
GHK-Cu, or 
SPARC120-122
GHK Cu2+-binding region of 
SPARC
Induces a wide range of cellular effects, including reducing 
inflammatory while increasing anti-inflammatory factors, 
increasing extracellular matrix protein production, and matrix 
metalloproteinase expression. In vivo effects have been 
shown ranging from increasing vascularization in the rabbit 
eye, increasing the rate of uncomplicated and diabetic wound 
healing, and inhibiting gastric ulcer formation
Pickart 
(2008)
Comb1 DINECEIGAPAGEETEVTVEGLEPG Combination of the 
epidermal growth factor -like 
domains of fibrillin 1 and 
tenascin X
Increases cell proliferation, tube formation, and sprouting 
compared to controls in vitro. Increased chemically impaired 
cutaneous wound healing when co-delivered daily with UN3
Demidova-
Rice et al. 
(2011, 2012)
UN3 NH2-ELLESYIDGRPTATSEYQTFFNPR- 
amide
Previously unknown peptide 
fragment from platelet lysate
Significantly increased cell migration, proliferation, and tube 
formation in vitro. Significantly increased vessel density in 
impaired cutaneous wounds. Increased chemically impaired 
cutaneous wound healing when co-delivered daily with Comb1
Demidova-
Rice et al. 
(2012)
KRX-725 MRPYDANKR Second intercellular loop of 
sphingosine 1-phosphate 
(S1P) 3
Increases aortic ring sprouting as compared to controls with 
greater smooth muscle cell co-localization to endothelial cells 
than VEGF. Increases in vascularization of the rabbit cornea 
were obtained by co-treatment with KRX-725 and VEGF or 
bFGF as compared to factors alone
Ben-Sasson 
et al. (2003)
Pep-12 NYLTHRQ Ig-like domain II of VEGF 
receptor 1
Facilitates integrin-mediated cell adhesion and cause tube 
formation in vitro. Significantly increases angiogenesis in the 
rabbit cornea as compared to controls, albeit to a lesser extent 
than VEGF
Soro et al. 
(2008)
LL-37 LLGDFFRKSKEKIGKEFKRIVQR 
IKDFLRNLVPRTES
The 134–170 amino acid 
region of the human cationic 
anti-microbial protein 18
Originally identified as an anti-microbial peptide produced in 
response to inflammation or infection, it was shown to have 
pro-angiogenic effects in addition to anti-microbial action. 
LL-37 caused dose-dependent increases in cell proliferation 
and increased collateral blood flow, capillary density, and blood 
velocity in a rabbit hind-limb ischemia model
Koczulla 
et al. (2003)
YR or RoY YPHIDSLGHWRR Identified by phage display 
for binding to endothelial 
cells
Increased cell proliferation and migration in vitro. Increases 
vessel density when injected into a mouse ear and hindlimb 
reperfusion when delivered intramuscularly
Hardy et al. 
(2007, 2008)
AcSDKP AcSDKP A naturally expressed 
regulator of hematopoiesis 
found in bone marrow
AcSDKP increases cell migration and tube formation, with 
increasing then decreasing responses as the concentration 
is increased beyond the optimal dose. Similar results were 
seen in vivo using the Matrigel plug assay, with greater 
vascularization induced with 10−9 M than 10−5 M of peptide
Liu et al. 
(2003)
A selection of pro-angiogenic peptides, all which are in pre-clinical testing. Standard amino acid abbreviations are used. C*, disulfide bridge; Ahx, aminohexanoic acid; Ac, acetyl.
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mimic PAB2-1c). Additionally, PAB2-1c is a multi-domain peptide, 
containing two copies of PDGF-BB153–162 as well as a heparin-binding 
domain RKRKLERIAR (Verrecchio et  al., 2000), which could be 
exploited for controlled release purposes (further discussed below).
GHK
The secreted protein acidic and rich in cysteine (SPARC) (also 
known as osteonectin) is an extracellular matrix protein expressed 
during embryogenesis and tissue repair/remodeling. In  vivo, 
SPARC is cleaved by proteases into distinct fragments, with frag-
ments from each domain producing drastically different cellular 
responses (Motamed, 1999). Fragments from the cysteine-rich 
follistatin-like region that contain the copper-binding sequence 
GHK have been shown to have numerous pro-angiogenic and 
healing effects, increasing fibroblast production of VEGF and 
FGF, increasing extracellular matrix production and remodeling, 
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increasing vessel formation in the rabbit cornea, accelerating 
dermal wound healing, increasing hair follicle growth, and acting 
as a chemoattractant for macrophages, capillary cells, and mast 
cells, to name a few (Pickart, 2008). While the delivery system, 
dose, and model varies widely across the many studies exploiting 
GHK and its analogues, the peptide is generally delivered using a 
controlled release system or by repeated administration (Pickart, 
2008). Interestingly, when coupled to alginate hydrogels, GHK 
increased VEGF and FGF production by mesenchymal stem cells 
(Jose et  al., 2014), potentially increasing their pro-angiogenic 
efficacy and capacity for tissue repair (Rustad et al., 2012; Hoffman 
et al., 2013). Together, the numerous and diverse effects of this 
peptide make it an intriguing drug for use in pro-angiogenic, 
wound repair, and tissue engineering applications.
Synergistic Effects Upon Delivery of Multiple Factors
Numerous peptides have improved efficacy upon co-delivery with 
other peptides or factors. Qk caused synergistic increases in cell 
migration when delivered with VEGF or FGF-2 (Finetti et al., 2012). 
While UN3 (a peptide fragment identified from platelet lysate) alone 
was able to increase vascularization of cutaneous wounds, increased 
wound quality was only observed when UN3 was co-delivered with 
Comb1 (a combination of the fibrillin 1 and tenascin X) (Demidova-
Rice et al., 2012). KRX-725 showed similar additive effects when 
co-delivered with bFGF, significantly increasing vascularization of 
the rabbit cornea as compared to delivery of the peptide or protein 
alone (Ben-Sasson et al., 2003). This suggests that pro-angiogenic 
peptides, similar to their protein counterparts, could benefit from 
controlled release strategies that deliver multiple factors, either all 
peptides, or a combination of peptides and proteins.
Delivery of multiple proteins from a material that more closely 
replicating their temporal expression in the pro-angiogenic signal-
ing cascade has been shown to improve pro-angiogenic effects as 
compared to singular protein delivery, or delivery of multiple pro-
teins without this temporal control (Mooney et al., 2007; Brudno 
et al., 2013). For example, delivery of VEGF followed by PDGF, 
which more closely recapitulates the native pro-angiogenic healing 
cascade (Figure 1), improves vessel density, size, and maturity as 
compared to delivery of either factor alone (Richardson et al., 2001; 
Sylven et al., 2007). Similarly, delivery of multiple pro-angiogenic 
(VEGF and Ang2) followed by pro-maturation (PDGF and Ang1) 
factors with temporal delivery motivated by healthy angiogenic 
signaling-induced formation of more mature, larger vessels than 
controls (Brudno et al., 2013). As previously discussed, one could 
envision exploiting peptide mimics of these two factors (Qk and 
PAB2-1c) similarly. Additionally, the Ang1 mimic T7 could be 
employed as a pro-maturation peptide delivered in conjunction 
with a pro-angiogenic peptide, such as Qk, as Ang1 is important for 
pericyte recruitment and vessel maturation/remodeling (Figure 1).
Drug Delivery Systems for  
Pro-Angiogenic Peptides
Drug delivery systems are often used to address delivery challenges 
associated with therapeutic efficacy. While the specific goal of 
each delivery system depends on the drug being delivered and 
its target tissue/disease state, the over-arching goal is to maintain 
or increase the efficacy of the therapeutic while minimizing or 
eliminating toxicity and side effects (Bader and Putnam, 2014). 
To achieve these goals, drug delivery systems can be designed to 
improve the solubility of the drug, protect it from degradation, 
increase its circulation/retention time, improve preferential tissue 
accumulation, and/or prolong its retention at the target site (Bader 
and Putnam, 2014). Of particular concern when delivering pro-
angiogenic drugs is off-target delivery, which could potentially 
encourage the development of tumors (Carmeliet and Jain, 2000), 
or increasing the severity of diseases associated with excessive 
angiogenesis, such as macular degeneration (Kent, 2014).
The most commonly exploited drug delivery systems can be 
broadly classified into three categories: orally delivered, soluble 
(or injectable), and depot-based implantable systems. Delivery 
of proteins and peptides using alternate entry routes (e.g., nasal, 
pulmonary, and transdermal) are not commonly exploited for 
pro-angiogenic applications, and are reviewed elsewhere (Agu 
et al., 2001; Shoyele and Cawthorne, 2006; Antosova et al., 2009). 
Methods to improve oral delivery of protein and peptide drugs 
have been recently reviewed (Al-Hilal et  al., 2013; Renukuntla 
et al., 2013). Du and Stenzel have published a thorough review 
that focuses on chemical conjugation methods for peptide drug 
delivery using soluble polymeric delivery systems (liposomes, 
nanoparticles, etc.) (Du and Stenzel, 2014). These soluble and oral 
delivery systems are less desirable for pro-angiogenic applications, 
such as cardiac ischemia and diabetic wounds, due to difficulty 
achieving preferential accumulation at target tissues, and previously 
mentioned concerns over systemic delivery of pro-angiogenic fac-
tors encouraging tumor development (Carmeliet and Jain, 2000).
Depot-Based Drug Delivery Systems
Depot-based delivery systems are associated with improved 
patient compliance and have been successfully used for decades 
for longitudinal delivery of drugs, such as contraceptives (Graesslin 
and Korver, 2008). This delivery route avoids the need for the 
drug to pass through the harsh conditions of the digestive system, 
and through the intestinal epithelium. Placing the drug delivery 
depot directly at the target tissue site allows preferential delivery 
to the target tissue, achieving higher doses and reducing unwanted 
off-target tissue side effects. Additionally, by designing the depot to 
contain a high dose of drug and slowly release it over time, a single 
treatment can maintain drug dose within the therapeutic window 
for extended durations (Bader and Putnam, 2014).
Osmotic pumps are commonly used to achieve prolonged 
drug delivery (Santulli et  al., 2009; Bader and Putnam, 2014). 
However, pumps must be removed after payload delivery, neces-
sitating additional surgeries. Biomaterial-based peptide delivery 
systems that provide longitudinal release are an alternate method 
to locally deliver proteins and peptides, and the use of degradable 
biomaterials avoids the need for surgical recovery. While many 
depot-based delivery systems are formed externally and then 
implanted, some biomaterials allow for in situ formation, where 
precursor material can be injected and then polymerized in place, 
allowing for minimally invasive implantation (Anseth et al., 2002), 
particularly attractive for cardiac applications.
Depot-based methods present many specific advantages for pro-
angiogenic therapies, including providing localized drug delivery 
FiGURe 2 | Schematic of drug release from biomaterial depots. Release 
of drugs from depot-based biomaterials can be controlled by a number of 
mechanisms. (A) Drug is encapsulated within a biomaterial with large enough 
mesh/pore size to allow for diffusive release of the encapsulated drug. (B) Drug 
is tethered to a biomaterial that degrades in response to enzyme expression 
and releases the drug upon degradation of the biomaterial. (C) Drug is tethered 
to the biomaterial by the enzymatically cleavable tether, and released upon 
linker cleavage. (D) Diffusive release of encapsulated drug is prolonged by 
affinity interactions between the material and the drug. (e) Diffusive release of 
encapsulated drug is prolonged by delayed dissolution of the drug. (F) Drug is 
encapsulated within a degradable biomaterial and released as the material 
degrades. Not to scale.
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thereby reducing concerns over off-target effects (Chu and Wang, 
2012). Depot methods can also provide the spatial and temporal 
delivery of factors necessary for the development of stable, func-
tional vessels (Mooney et al., 2007; Brudno et al., 2013). A schematic 
depicting select modes drugs have been released from biomaterial 
depots is shown in Figure 2. To date, the pro-angiogenic biomaterials 
field has largely focused on delivery of full-length proteins, and few 
depot-based methods for peptides have been developed (Du and 
Stenzel, 2014). This is likely due to the previously discussed histori-
cal difficulties associated with the use of peptide drugs. However, the 
recent identification of numerous pro-angiogenic peptides (Table 2) 
combined with new and improved peptide synthesis strategies have 
opened up an entirely new class of pro-angiogenic drugs for delivery. 
Herein, we focus on those biomaterials that have been developed for 
delivery of pro-angiogenic peptides, and those that could be easily 
adapted for peptide delivery, laying the foundation for a whole host 
of potential pro-angiogenic therapies.
Hydrogels
Hydrogels are highly hydrated crosslinked polymeric networks 
often used to provide sustained, localized drug delivery. The 
highly hydrated nature of hydrogels is similar to native tissues, 
and the aqueous network can stabilize peptide and protein drugs. 
Depending on the polymer used to form the gel, hydrogels can 
have highly tunable physical and chemical properties, to provide 
a wide degree of control over hydrogel properties and drug release 
behavior (Lin and Anseth, 2009b; Liechty et al., 2010).
Hydrogels can be formed using a variety of approaches. These 
include physical crosslinks (entanglements, hydrogen bonding, 
or hydrophobic forces), covalent bonds, ionic crosslinks, or a 
combination of these approaches (Peppas et al., 2006). These gels 
may be physically stable, or may degrade or dissolve, either due to 
the nature of the polymer used, or as a result of specific chemical 
functionalities introduced for degradability. While a wide range of 
polymers have been used to form hydrogels, they can be broadly 
classified as either natural or synthetic polymers, although “hybrid 
hydrogels” can be formed that use both natural and synthetic 
polymers (Slaughter et  al., 2009). Select examples of hydrogels 
used for controlled drug delivery are listed in Table 3.
Generally speaking, the rate of drug release from hydrogels is 
controlled by the diffusion of drug out of the crosslinked gel network 
(Figure 2A) (Slaughter et al., 2009). However, diffusion alone often 
does not facilitate long-term delivery of small drugs, such as peptides 
and small molecule drugs, as hydrodynamic radius is proportional 
to release rate, resulting in faster release relative to larger molecules, 
such as proteins (Lustig and Peppas, 1988). Therefore, to deliver 
these small drugs from hydrogels, more advanced modifications 
are often required to control the release (Figures 2B–E).
Naturally derived polymers
Polymers from natural sources, such as alginate, agarose, chitosan, 
collagen, digested extracellular matrix, fibrin, gelatin, and hya-
luronic acid (HA) can be used to form hydrogels. As they are 
derived from plant or animal sources, natural polymers generally 
have low toxicity and good biocompatibility. However, the physi-
cal and chemical properties of naturally derived hydrogels can be 
difficult to control. Additionally, due to their biological sources, 
these materials often present signals that can be recognized by cells 
TABLe 3 | Hydrogel-based biomaterials for controlled drug delivery.
Type Polymer Drug delivered Drug type Mode of release Reference
Natural 
hydrogels
Alginate VEGF Protein Diffusive Silva and Mooney 
(2007, 2010)
Alginate VEGF and PDGF Dual proteins Diffusive Sylven et al. (2007)
Fibrin VEGF Protein Proteolytic 
degradation
Ehrbar et al. (2004)
Extracellular matrix bFGF Protein sGAG-binding 
affinity
Seif-Naraghi et al. 
(2012)
Extracellular matrix HGF-f Protein 
fragment
sGAG-binding 
affinity
Sonnenberg et al. 
(2015)
Gelatin FGF-2 and G-CSF Dual proteins Diffusive and ionic 
interactions
Layman et al. (2009)
Hyaluronic acid TGF-β1 Protein Heparin-binding 
affinity
Jha et al. (2015)
Matrigel T7 Vasculotide PEG-peptide 
tetramer
Diffusive Van Slyke et al. (2009)
Matrigel Qk Peptide Diffusive Santulli et al. (2009)
Synthetic 
hydrogels
Poly(ethylene glycol) multiacrylate and dithiolthreitol hGH Protein Dissolution and 
diffusion
van de Wetering et al. 
(2005)
Poly(ethylene glycol vinyl sulfone and proteolytically 
cleavable peptide
VEGF Protein Enzymatically 
responsive
Zisch et al. (2003)
Poly(ethylene glycol) diacrylate and proteolytically 
cleavable peptide
VEGF Protein Enzymatically 
responsive
Phelps et al. (2010)
Poly(ethylene glycol) norbornene and enzymatically 
cleavable peptide
Qk, SPARC113, SPARC118, and 
model peptides
Peptide Enzymatically 
responsive
Van Hove et al. (2014)
Poly(N-isopropylacrylamide-co-propylacrylic acid-co-
butyl acrylate) 
bFGF Protein pH-responsive 
and diffusive
Garbern et al. (2010), 
Murry et al. (2011)
Combinatory/
hybrid 
hydrogels
Poly(ethylene glycol)-bis-butanoic acid and 
hydrazide-functionalized heparin
VEGF Protein Heparin-binding 
affinity
Tae et al. (2006)
Multi-arm poly(ethylene glycol) thiol and dextran vinyl 
sulfone
IgG, BSA, Lysozyme, and bFGF Protein Diffusive Hiemstra et al. (2007)
Poly(ether)urethane–polydimethylsiloxane + fibrin VEGF and bFGF Dual proteins Diffusive Losi et al. (2010)
Hyaluronic acid + PEG VEGF and bFGF Protein Heparin-binding 
affinity
Pike et al. (2006)
Select examples of hydrogel-based biomaterials used for controlled drug delivery.
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within the body, which can be advantageous or disadvantageous 
depending upon the application (Peppas et al., 2006).
Alginate
Alginate is a naturally occurring linear polysaccharide that is 
soluble in water, but due to negatively charged side groups can be 
ionically crosslinked by the addition of divalent cations, such as 
Ca2+. While they are generally biocompatible, without additional 
modification alginate hydrogels undergo slow and uncontrolled 
degradation in  vivo (Bouhadir et  al., 2001; Silva and Mooney, 
2007). Alginate hydrogels have been used for the controlled 
delivery of growth factors in a number of studies, and have shown 
the importance of extended delivery of VEGF to ischemic tissue 
(Silva and Mooney, 2007, 2010). Additionally, alginate hydrogels 
delivering VEGF followed by PDGF resulted in the same capil-
lary density within infarcted tissues versus gels delivering VEGF, 
but significantly improved the number of mature vessels over 
gels delivering either PDGF or VEGF alone (Sylven et al., 2007), 
demonstrating the improvement in angiogenesis that can be 
obtained by more closely recapitulating the natural pro-angiogenic 
signaling cascade reviewed in Figure 1. While able to controllably 
deliver large proteins, unmodified alginate hydrogels are not well 
suited for delivery of peptide drugs. The mesh size of alginate 
hydrogels varies depending on the percentage of alginate used, 
but is generally on the order of magnitude of 10 nm (Turco et al., 
2011). This facilitates hindered diffusion of larger proteins, such 
as VEGF and PDGF, but would likely be less successful delivering 
small peptides.
Extracellular matrix
Hydrogels derived from decellularized, digested extracellular 
matrix (ECM) have also been exploited for delivery of pro-
angiogenic factors. These materials provide a physical structure 
that supports cell infiltration and vascularization and provides 
structural support to the tissue, which has been shown beneficial 
in limiting post-myocardial infarction damage to cardiac tissue 
(Okada et  al., 2010; Singelyn et  al., 2012). These materials are 
highly heterogeneous, and some ECM-based materials have caused 
inflammatory responses in vivo (Seif-Naraghi et al., 2012), while 
others reduce the extent of chronic inflammation (Faulk et  al., 
2014). Decellularized, digested porcine pericardiac tissue has been 
exploited for the sustained delivery of bFGF. Release of bFGF from 
the ECM material occurred at approximately half the rate as from 
collagen gels, likely due to affinity interactions between bFGF and 
sulfated glycosaminoglycans (GAGs) within the ECM (Figure 2D). 
Upon injection into cardiac tissue, approximately three times more 
bFGF was retained after 5 days when the protein was delivered in 
the ECM material compared to direct injection. Additionally, the 
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bFGF-releasing ECM significantly increased the number of small 
(10–50 μm) vessels within the tissue. However, the bFGF-releasing 
ECM caused a significant increase in inflammation, undesirable in 
many tissue repair applications (Seif-Naraghi et al., 2012).
Similar porcine pericardial ECM hydrogels were used for 
sustained delivery of a hepatocyte growth factor (HGF) frag-
ment (HGF-f), which shows similar bioactivity to full-length 
HGF while being less than half the size of the full-length protein 
(Liu et al., 2014). The ECM-based hydrogel provided sustained 
release of HGF-f, releasing ~30% over 5 days and significantly 
increased arteriole density in infarcted cardiac tissue. However, 
it only caused trending improvements in function as assessed by 
ejection fraction (Sonnenberg et al., 2015). The HGF-f released 
from these gels is still substantial larger than a peptide (~40 kDa), 
and sustained delivery of smaller peptides from these hydrogels 
would likely not occur without similarly exploiting GAG affinity 
interactions. This would require modification of the peptide with 
a heparin-binding sequence, such as RKRKLERIAR (Lin et al., 
2007), (XBBXBX)n, or (XBBXXBX)n, where X is uncharged or 
hydrophobic, and B is a basic amino acid (Verrecchio et al., 2000). 
Additionally, any inflammatory reaction to these ECM materials 
would need to be addressed, as this is a significant concern for 
translation.
Fibrin
Fibrin hydrogels have been used for a number of biomaterial and 
drug delivery applications. Similar to fibrin clots formed after 
vascular injury, fibrin hydrogels are formed by reacting fibrinogen 
and thrombin (Ehrbar et al., 2004; Schmoekel et al., 2005). They 
are highly biocompatible, and can be degraded by plasmin and 
other enzymes in the body (Ye et al., 2000; Ahmed et al., 2007). 
In an attempt to improve the efficacy of VEGF by providing 
long-term delivery of the growth factor, Ehrbar et al. conjugated 
VEGF to a fibrin matrix such that the VEGF molecule could only 
be released when the fibrin matrix was proteolytically degraded 
(Figure 2B). This greatly extended the duration of VEGF release, 
and the fibrin-released VEGF increased the formation of new 
arterial and venous structures within the chick chorioallantoic 
membrane, while passively released VEGF (Figure 2A) primar-
ily resulted in chaotic changes to the vasculature (Ehrbar et al., 
2004). This enzymatically responsive gel could easily be adapted 
for delivery of pro-angiogenic peptides. By including the factor 
XIIIa substrate NQEQVSPL onto either the C- or N-termini of 
the peptide, peptides could similarly be covalently integrated 
into the fibrin network via factor XIIIa activation (Zisch et al., 
2001). However, proteins/peptides released from these gels contain 
residual fragments of the fibrin gel, which could affect bioactivity. 
Testing of released VEGF showed comparable bioactivity to non-
tethered, encapsulated protein (Ehrbar et al., 2004), but this would 
not necessarily be the case for all drugs.
One disadvantage to the use of fibrin gels is that they do not 
afford control over the rate of gel degradation and associated 
drug release. Some degree of control over the time course of 
VEGF release was achieved by introducing a plasmin-sensitive 
substrate between the growth factor and the Factor XIIIa sub-
strate (NQEQVSPL-LIK↓MKP-VEGF, ↓ indicates cleavage site) 
(Ehrbar et al., 2005). However, this modification to the system only 
accelerated growth factor release by ~25%, and does not provide a 
means to easily tune protein/peptide release kinetics.
Gelatin
Gelatin is a natural hydrogel derived from collagen used in drug 
delivery applications because of its biocompatibility and control-
lable degradation (Tabata and Ikada, 1998; Young et al., 2005). 
Covalently crosslinked gelatin hydrogels were exploited for the 
controlled delivery of FGF-2 and granulocyte-colony stimulating 
factor (G-CSF). While release of both FGF-2 and G-CSF were 
diffusion mediated, FGF-2 release was delayed as compared to 
G-CSF, likely due to ionic interactions between the anionic gelatin 
and cationic FGF-2 (Figures  2A,D). Hydrogels releasing both 
growth factors improved ischemic hind limb reperfusion assessed 
via increased capillary density and maturity as compared to PBS or 
singularly delivered growth factor controls (Layman et al., 2009). 
By processing collagen in either acidic or alkaline conditions, its 
isoelectric point can be modified. This allows oppositely charged 
molecules to interact with the gelatin and form a polyion complex, 
extending release by affinity interactions (Tabata and Ikada, 1998; 
Young et al., 2005). Yamamoto et al. showed this when they dem-
onstrated that encapsulation of bFGF and transforming growth 
factor- β1 (TGF-β1) in acidic gelatin hydrogels prolonged in vivo 
delivery as compared to direct injection. However, despite similar 
isoelectric points, prolonged delivery of bone morphogenetic 
protein-2 (BMP-2) and VEGF was not achieved possibly due 
to differences in 3D structure and charge exposure (Yamamoto 
et  al., 2001). In addition to being unable to deliver the potent 
pro-angiogenic protein VEGF, these gelatin hydrogels are not 
ideal for the delivery of smaller peptides. The strength of the 
interaction between the drug and the gelatin decreases as the size 
of and number of charges on the drug being delivered decreases 
(Tabata and Ikada, 1998), making it likely that gelatin would not 
prolong the delivery of smaller peptides. This was illustrated by 
Saramento et al., who attempted to use polyion interactions to 
deliver insulin, which at 51 amino acids is on the cusp of what is 
considered a peptide versus a protein (Sarmento et al., 2007). By 
combining this negatively charged peptide with negatively charged 
fibrin and positively charged chitosan, nanoparticles were formed 
crosslinked by electrostatic forces. However, release of the peptide 
was rapid, with ~60% released in 2 h, demonstrating the limitations 
of using ionic interactions to control the release of small peptides 
(Sarmento et al., 2007).
Hyaluronic acid
Hyaluronan or HA is a naturally occurring component of the 
extracellular matrix. HA degradation in  vivo is mediated by 
hyaluronidases, six enzymes that hydrolyze HA (Stern, 2004). The 
released HA fragments have been shown to have pro-angiogenic 
effects in  vivo (Montesano et  al., 1996), making it a promising 
material for delivery of pro-angiogenic factors, as both the mate-
rial and drug being delivered could contribute to the desired 
pro-angiogenic response. However, this convolutes drug-specific 
effects, and excessive pro-angiogenic signaling can sometimes 
lead to the development of leaky vasculature (Yancopoulos et al., 
2000). HA hydrogels with mesh sizes and degradation controllable 
based upon the degree of HA methacrylation can be formed by 
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UV polymerization. These hydrogels exhibit good biocompat-
ibility upon subcutaneous implantation (Leach et al., 2003) but 
their mesh sizes are very large (~600 nm), causing rapid release 
of encapsulated proteins (Leach and Schmidt, 2005) and making 
this an unattractive approach for delivery of small pro-angiogenic 
peptides. Enzymatically degradable HA hydrogels were formed by 
functionalizing HA with acrylate groups and reacting with di-thiol 
containing matrix metalloproteinase (MMP)-degradable crosslink-
ing peptides and thiolated heparin for affinity-controlled protein 
release (Figure 2D). Release of encapsulated TGF-β1 was prolonged 
over >3 weeks, with the release rate affected by the molecular weight 
of heparin used, as well as the amounts of heparin and TGF-β1 
used in hydrogel formation (Jha et al., 2015). While this study did 
not investigate in vivo degradation or the pro-angiogenic/wound 
healing effects of the material, it did demonstrate the highly tunable 
protein release that can be achieved using heparin-functionalized 
HA hydrogels. However, due to the number of growth factors that 
have affinity for heparin (Peysselon and Ricard-Blum, 2014), it is 
possible that host proteins with greater affinity for heparin may 
displace drug molecules when introduced in vivo.
Supramolecular interactions of adamantine and cyclodextrin 
have also been exploited to form shear-thinning, self-healing 
HA hydrogels, by combining adamantane- and cyclodextrin-
functionalized HA. The physical properties of these HA gels, such 
as stiffness and degradation rate, can be modified by varying the 
weight percentage of HA, as well as the extent of functionalization 
(Rodell et al., 2013). These hydrogels can be rendered enzymatically 
degradable by tethering the adamantane to the HA by an MMP-
degradable peptide sequence (Rodell et al., 2015). This material 
holds great promise for the delivery of pro-angiogenic peptides due 
to the affinity interactions of cyclodextrin with peptides (Tiwari 
et al., 2010), particularly those containing hydrophobic and aro-
matic amino acids (Castronuovo et al., 1995; Aachmann et al., 
2012). However, due to these fairly non-specific interactions, these 
materials have the same potential concern as heparin gels whereby 
host molecules may displace drug molecules, drastically affecting 
drug release. Many HA hydrogels are formed using poly(ethylene 
glycol) (PEG) crosslinkers, and are further discussed in the Section 
“Hybrid materials” below.
Matrigel
Matrigel is a mixture of extracellular matrix molecules produced 
by Engelbreth–Holm–Swarm (EHS) mouse sarcoma cells that is 
soluble at 4°C but polymerizes when incubated at 37°C. Due to the 
gentle polymerization conditions required to form gels, and ability 
of a variety of cells to interact with the gel during vascularization, 
Matrigel is commonly used in  vivo to provide diffusive release 
(Figure 2A) and evaluate the efficacy of pro- and anti-angiogenic 
proteins and peptides (Kleinman and Martin, 2005; Santulli et al., 
2009; Van Slyke et  al., 2009). However, Matrigel has inherent 
biological activity that varies between production lots based on 
residual-growth factors left in the matrix (Kleinman and Martin, 
2005). Concerns over its tumor source prevents Matrigel from 
being used for translational drug delivery purposes, and many 
studies using Matrigel to deliver therapeutic factors in vivo do not 
characterize the release of the factor from the gel (Santulli et al., 
2009; Van Slyke et al., 2009).
Synthetic polymers
Many synthetic polymers have also been exploited for controlled 
drug delivery. As compared to natural polymers, synthetic poly-
mers afford a greater degree of control over resulting hydrogel 
networks. Hydrogel properties, such as crosslinking density, 
mechanical strength, degradation, drug release profile, and even 
stimuli-responsive behavior can be controlled by altering the 
composition of the polymer network. While many synthetic poly-
mers are bio-inert, they are frequently engineered to incorporate 
functional groups that allow cells to bind to and interact with the 
hydrogel (Peppas et al., 2006).
Poly(ethylene glycol)
Poly(ethylene glycol) hydrogels are a commonly used synthetic 
biomaterial for drug delivery (Peppas et al., 2006; Lin and Anseth, 
2009b; Slaughter et al., 2009). PEG hydrogels are highly hydro-
philic, inert, and biocompatible, and PEG has been approved 
by the FDA for a number of clinical uses (Peppas et al., 2006). 
Additionally, PEG hydrogels have been shown to have highly 
tunable degradation profiles and mechanical properties (Lin and 
Anseth, 2009b). While PEG hydrogels are inherently bio-inert, 
they can be functionalized with cell adhesion molecules, such 
as the RGD peptide to facilitate cellular interactions (Hern and 
Hubbell, 1998).
To facilitate hydrogel formation, PEG can be crosslinked by two 
mechanisms: step-growth and chain-growth, or a combination 
of the two, termed mixed-mode. Chain-growth polymerization 
occurs when PEG macromers contain self-reactive terminal 
groups (predominantly acrylates and methacrylates). These gels 
do not require the use of an additional crosslinking agent, but 
produce heterogeneous networks structures that contain dense 
crosslinking regions (Lin and Anseth, 2009b; Van Hove et  al., 
2013). Step-growth polymerization occurs when PEG macromers 
preferentially react with a second functionality on a crosslinker 
(thiol-acrylate, thiol-norbornene, alkyne-azide, tetrazine-azide, 
etc.). Step-growth polymerization provides an easy method to 
incorporate peptides into hydrogel networks; by exploiting thiol 
groups on cysteine amino acids and unsaturated carbon bonds 
of functionalities introduced to PEG (norbornene, acrylate, etc.), 
peptides can be incorporated into hydrogels as crosslinking agents 
or tethered pendant groups (Fairbanks et al., 2009; Shih and Lin, 
2012; Van Hove et al., 2014).
PEG hydrogels for pro-angiogenic drug delivery
Poly(ethylene glycol) hydrogels have been used to deliver a num-
ber of therapeutic molecules. This specific topic was previously 
reviewed by Lin and Anseth (2009b). Herein, we will focus on 
recent developments and their specific utility in pro-angiogenic 
applications. Controlled delivery of human growth hormone 
(hGH) from step-growth polymerized PEG hydrogel networks 
formed by reacting multi-arm PEG acrylate (PEGA) with dithi-
othreitol (DTT) has been demonstrated. Precipitation of hGH with 
Zn2+ prior to encapsulation protected the protein during polym-
erization and delayed release from the gels via delayed dissolution 
(Figure 2E). Varying the PEG macromers used to form hydrogels 
controlled hydrogel swelling ratios, which subsequently extended 
protein release beyond 25  days (van de Wetering et  al., 2005). 
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While all gels studied were hydrolytically degradable, only one 
macromer configuration produced gels that degraded and release 
drug over similar time frames (21 days). The other gels developed 
persisted long after releasing their payload: gels releasing hGH 
over 1 day took 21 days to degrade, and gels releasing hGH over 
~8 weeks (extrapolated based on first-order release data) were still 
intact after 15 weeks (van de Wetering et al., 2005). hGH has been 
shown to have both pro- and anti-angiogenic effects depending if 
it is presented in full-length protein or as the 16 kDa N-terminal 
fragment (Struman et al., 1999). Therefore, while these hydrogels 
were intended for treatment of growth hormone deficiency, 
Turner’s syndrome, and chronic renal failure, they could also 
present a promising pro-angiogenic strategy. While to the best 
of our knowledge, this delayed dissolution approach has not yet 
been exploited for delivery of peptide drugs, it could theoretically 
be used for delivery of hydrophobic peptides, such as Qk, which 
has 53% hydrophobic amino acids (Lehninger et al., 2000) and a 
Hopp–Woods average value of −0.2 (Hopp and Woods, 1981). 
Additionally, Qk forms an α-helix, which has been shown to 
increase peptide self-assembly in aqueous solution (Kisiday et al., 
2002), making it an attractive candidate for delivery using this 
delayed dissolution approach.
poly(ethylene glycol) hydrogels designed by West and Hubbell 
to degrade in response to local enzyme levels have recently been 
adapted for drug delivery applications. In their seminal work, 
enzymatically responsive PEG macromers were formed by reacting 
a degradable peptide with PEG, forming an peptide-PEG-peptide 
block copolymer which was then functionalized with terminal 
acrylate groups, allowing for hydrogel formation (West and 
Hubbell, 1999). Building upon this foundation, additional enzy-
matically responsive PEG hydrogels have been developed, with 
the specific degradable peptide used controlling enzyme specific 
and hydrogel degradation kinetics (Hubbell et al., 2003; Patterson 
and Hubbell, 2010).
As a pro-angiogenic approach, Zisch et al. used Michael-type 
addition reactions to form PEG hydrogels that degrade and release 
VEGF in response to local enzymes. Multi-arm PEG vinyl sulfone 
was reacted with cysteine flanked MMP-degradable peptides, as 
well as VEGF engineered with a plasmin-sensitive tether and 
terminal cysteine. This formed hydrogels that released VEGF 
both upon MMP-mediated hydrogel degradation and plasmin-
mediated tether cleavage (Figures 2B,C). When used in the chick 
chorioallantoic membrane assay, VEGF-conjugated hydrogels 
resulted in the formation of new vessels highly localized to the 
hydrogel, and improved vessel infiltration upon subcutaneous 
implantation as compared to controls (Zisch et al., 2003). These 
hydrogels simultaneously degrade and release the pro-angiogenic 
protein, attractive behavior for an implantable or injectable drug 
delivery system as the gel will not persist after delivering its payload. 
This system could be easily adapted for delivery of pro-angiogenic 
peptides like those shown in Table 2. However, some of the drug 
is release tethered to a PEG molecule. While testing showed that 
VEGF remained bioactive with the PEG “tail” (Zisch et al., 2003), 
this would not necessarily be the case for all proteins or peptides.
Phelps et al. also exploited PEG hydrogels to provide enzymati-
cally responsive protein release. By reacting proteolytically cleav-
able peptide linkers with acrylate-PEG-N-hydroxysuccinimide 
(NHS), an acrylate–PEG-peptide–PEG-acrylate macromer was 
formed. These macromers were then polymerized to form enzy-
matically degradable PEG hydrogels, with VEGF tethered via a 
non-degradable PEG linker, resulting in protein release only when 
the gel is degraded (Figure 2B). Similar to the system developed by 
Zisch et al., the VEGF is released from the gel tethered to residual 
PEG macromers. While enzymatically responsive hydrogel degra-
dation was shown, protein release was not quantified in parallel. 
Nevertheless, there was significantly greater vascular ingrowth 
into VEGF-releasing hydrogel as compared to the enzymatically 
responsive hydrogels alone. Additionally, treatment with the 
enzymatically responsive, VEGF-releasing hydrogels caused 
greater reperfusion of ischemic hindlimb tissue than bolus VEGF 
delivery (Phelps et al., 2010).
Our group recently developed hydrogels providing sustained, 
enzymatically responsive peptide release (Figure  2B). Peptide 
drugs were synthesized flanked by enzymatically degradable 
sequences with terminal cysteine amino acids (C-degradable 
linker-drug-degradable linker-C). This allowed for step-growth 
thiolene reactions with multi-arm norbornene-functionalized PEG 
(PEGN). These hydrogels demonstrated enzymatically responsive 
degradation and peptide release, and were confirmed to release 
bioactive components able to induce tube network formation 
in vitro. Similar to the previously discussed systems, simultane-
ous hydrogel degradation and peptide release occurs. However, in 
this system, the peptide drugs are released with only four amino 
acids residues on either side of the drug, rather than entire PEG 
macromers. These residual amino acids still had a substantial effect 
of peptide bioactivity, with only three of the six pro-angiogenic 
peptides screened retaining bioactivity in vitro. While this work 
generated a novel biomaterial to provide enzymatically responsive 
delivery of peptide drugs and identified key drug properties that 
affect gel behavior, it did not investigate hydrogel pro-angiogenic 
efficacy in vivo (Van Hove et al., 2014).
pH and temperature-responsive materials have also been 
exploited for controlled delivery of pro-angiogenic factors. 
Temperature and pH-responsive copolymers were formed from 
N-isopropylacrylamide (NIPAAM), propylacrylic acid (PAA), and 
butyl acrylate (BA) monomers [p(NIPAAm-co-PAA-co-BA)]. 
These copolymers form physical hydrogels (undergoing solution-
to-gel, or sol-to-gel, transition) as temperature is increased and 
pH decreased, with the transition point affected by the relative 
amounts of each monomer used. p(NIPAAm-co-PAA) (83 mol% 
NIPAAm, 17 mol% PAA, 37 kDa) copolymers produced hydrogels 
that released encapsulated VEGF via diffusion over ~7 days at pH 
7.4 and over ~3 weeks when pH was lowered to 5 or 6, pH levels 
consistent with ischemic tissue microenvironments (Garbern 
et al., 2010). Similar p(NIPAAm-co-PAA-co-BA) copolymers (67 
mol% NIPAAm, 18 mol% PAA, 15 mol% BA, 28 kDa) delivered 
encapsulated bFGF in vivo to infarcted myocardium over ~7 days, 
and improved fractional shortening of and blood flow to the heart, 
as well as capillary and arteriolar densities as compared to controls 
(Murry et  al., 2011). pH-responsive nanospheres formed from 
p(pAA-PEG) have been used to provide stimuli-responsive release 
of insulin (Foss et al., 2004), demonstrating the potential of these 
similar pH-responsive hydrogels for the delivery of pro-angiogenic 
peptide drugs.
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Hybrid materials
Combinations of natural and synthetic polymers have also been 
used to form hybrid hydrogels for controlled drug delivery. Heparin 
is often exploited as a natural polymer, as many pro-angiogenic 
proteins contain heparin-binding domains. Via heparin-protein 
affinity interactions, protein release can be sustained for days to 
weeks, depending upon the protein, amount of heparin included, 
and the tissue microenvironment. For example, covalently 
crosslinked heparin-PEG gels were formed by step-growth reac-
tions between hydrazide-functionalized heparin (Hep-ADH) and 
poly(ethylene glycol)-bis-butanoic acid (SBA-PEG-SBA). After 
gel formation, gels were partially dried and injected with a high 
concentration of VEGF before being incubated overnight to allow 
the protein to equilibrate within the gel. Release of VEGF from 
these hydrogels was nearly linear and occurred over >3 weeks, 
with the extended release attributed to affinity interactions between 
VEGF and heparin (Figure 2D). Subcutaneous implantation of 
the hydrogels showed increased CD31-staining as compared to 
control gels, indicating increased vessel formation (Tae et al., 2006).
Numerous proteins beyond VEGF contain heparin-binding 
domains (Peysselon and Ricard-Blum, 2014), and as a result, 
heparin affinity has been exploited for controlled delivery of a 
variety of proteins from a number of materials. This includes 
delivery of bFGF and BMP-2 from PEG hydrogels (Benoit and 
Anseth, 2005; Benoit et  al., 2007; Nie et  al., 2007), bFGF and 
β-nerve growth factor (β-NGF) from fibrin hydrogels (Sakiyama-
Elbert and Hubbell, 2000a,b), and transforming growth factor β1 
(TGF-β1), FGF-2, VEGF, and BMP-2 from alginate hydrogels 
(Jeon et al., 2011), all which incorporated heparin functionalities 
to prolong growth factor delivery. These materials are well suited 
for delivery of pro-angiogenic peptides, such as PAB2-1c, which 
contains the heparin-binding region RKRKLERIAR (Lin et  al., 
2007). Additional pro-angiogenic peptides could be delivered from 
heparin-functionalized hydrogels by including this or another 
heparin-binding sequence (Verrecchio et al., 2000) on either the 
C- or N-termini of the drug sequence, provided the addition of 
the heparin-binding region did not inhibit peptide bioactivity. 
However, as previously discussed, materials exploiting heparin 
affinity have the potential to sequester a variety of host proteins 
with affinity for heparin (Peysselon and Ricard-Blum, 2014).
Similarly, short peptides have been identified that mimic the 
heparin-binding capacity of VEGF (Maynard and Hubbell, 2005) 
and NGF (Willerth et al., 2007). By conjugating these peptides to 
hydrogels, affinity-controlled release of NGF from fibrin hydrogels 
(Willerth et al., 2007) and bFGF from PEG hydrogels (Lin and 
Anseth, 2009a) was demonstrated. While not explicitly used for 
pro-angiogenic applications, the potential for these approaches to 
deliver a number of pro-angiogenic proteins make them promising 
materials that could be further exploited for pro-angiogenic appli-
cations. However, these binding peptides would not necessarily 
have the same ability to bind and control the release of peptides 
mimics, as these mimics do not necessarily contain the region 
responsible for the drug-binding peptide interaction.
Other hybrid materials approaches for pro-angiogenic factor 
release include step-growth PEG-dextran hydrogels. These net-
works were formed by Michael Addition reactions between dex-
tran vinyl sulfone (dex-VS) and multi-arm PEG thiol. Controlling 
the molecular weight of the dextran molecule and the degree of 
substitution was shown to control hydrogel degradation kinetics 
and delivery of encapsulated proteins, such as immunoglobulin 
G (IgG) and bovine serum albumin (BSA). Lysozyme and bFGF 
release was achieved over 2 weeks to 1 month, with release rates 
affected by hydrogel composition. While the ability of the bFGF-
releasing hydrogels to induce angiogenesis was not studied in vivo, 
this material successfully delivered the pro-angiogenic factor over 
28 days with first-order release kinetics, with hydrogel degrada-
tion occurring over a similar time scale (Hiemstra et al., 2007). 
These dextran-PEG hydrogels release encapsulated protein by 
hindered diffusion (Figure 2A), and would likely release peptides 
at an accelerated rate due to the smaller size of the peptide drugs. 
However, it is possible that extended release could be achieved 
by further increasing the degree of substitution on the dextran 
or decreasing the molecular weight, both of which prolonged the 
protein delivery (Hiemstra et al., 2007).
Hybrid scaffolds have been formed using semi-interpenetrating 
polymeric network (semi-IPN) of poly(ether)urethane-polydi-
methylsiloxane (PEtU-PDMS) networks coated with protein-laden 
fibrin gels. These materials combined the mechanical strength of 
the PEtU-PDMS scaffold with controlled release provided by fibrin 
gels. This combination material provided simultaneous release of 
bFGF and VEGF, and significantly improved capillary density and 
perfusion of ischemic murine hind limbs as compared to controls 
(Losi et al., 2010). However, these materials must be formed ex 
vivo, and the PEtU-PDMS scaffold persists over a longer time 
scale (~6–24 months) (Soldani et al., 2010) than they deliver the 
drug (~1–2 weeks) (Losi et al., 2010). These scaffolds relied on 
diffusional release of the protein from the fibrin gels, rather than 
covalently linking the protein to the gel as discussed in the Section 
“Fibrin.” This makes them an unattractive approach for delivery 
of pro-angiogenic peptides, as the release of the drug is governed 
by diffusion (Figure  2A) rather than degradation, and would 
likely result in accelerated release of pro-angiogenic peptides. 
Alternately, one could envision combining the enzymatically 
responsive fibrin material used by Zisch et al. and Ehrbar et al. 
with the PDMS scaffold exploited here to combine the benefits 
of prolonged, enzymatically responsive drug delivery with the 
strength of the PDMS scaffold (Zisch et al., 2001; Ehrbar et al., 
2004, 2005).
Many HA-based hydrogels are crosslinked by functionalizing 
HA and PEG with mutually reactive groups (Peattie et al., 2004; Cai 
et al., 2005; Pike et al., 2006; Riley et al., 2006; Hosack et al., 2008). 
Hydrogels have been formed by reacting thiol-functionalized HA 
with PEG diacrylate (Peattie et al., 2006; Pike et al., 2006; Riley 
et al., 2006; Hosack et al., 2008), hydrazide-functionalized HA with 
PEG propiondialdehyde (Peattie et al., 2004), and methacrylate-
functionalized HA with PEGA (Leach and Schmidt, 2005). HA 
hydrogels containing tethered gelatin and heparin were formed 
containing encapsulated VEGF or bFGF, and showed extended 
release of encapsulated protein, with tunable release varying from 
19 to 96% after 42 days. Inclusion of thiol-functionalized gelatin 
increased the rate of protein release, while increasing amounts of 
heparin decreased the rate of drug delivery, with similar trends 
observed for both VEGF and bFGF. Heparin-functionalized HA 
gels releasing VEGF and bFGF both increased vascularization index 
TABLe 4 | Scaffold-based biomaterials for controlled drug delivery.
Polymer Drug 
Delivered
Drug 
Type
Mode of release Reference
Poly(lactide-co-
glycolide) (PLG)
VEGF Protein Scaffold degradation Sun et al. 
(2005)
PLG VEGF and 
PDGF
Dual 
proteins
Diffusion and scaffold 
degradation
Mooney 
et al. (2007)
PLG VEGF and 
PDGF
Dual 
proteins
Diffusion and scaffold 
degradation
Richardson 
et al. (2001)
PLG VEGF/Ang2 
and PDGF/
Ang1
Multiple 
proteins
Diffusive and scaffold 
degradation
Brudno 
et al. (2013)
Select examples of scaffold-based biomaterials used for controlled drug delivery.
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28 days after implantation in the mouse ear, but vessel density was 
unaffected (Pike et al., 2006). Excitingly, HA hydrogels crosslinked 
with PEG releasing encapsulated VEGF and/or keratinocyte growth 
factor (KGF) showed an additive increase in vessel number after 
implantation in the mouse ear when compared to HA gels, VEGF, 
or KGF alone. However, this study did not report the rate of drug 
release or degradation of the material (Peattie et al., 2006). These 
hydrogels could potentially be adapted for peptide delivery, but 
would require similar modification of peptides with a heparin-
binding region as discussed above, to facilitate extended release.
Scaffold-Based Systems
Many studies have exploited poly(lactide-co-glycolide) (PLG) 
scaffolds for drug delivery applications. PLG materials are bio-
degradable, biocompatible, and have received FDA approval for 
drug delivery applications (Jain, 2000; Makadia and Siegel, 2011). 
By altering the relative amounts of poly(lactic acid) (PLA) and 
poly(glycolic acid) (PGA) in the copolymer, the rate of degradation 
and subsequent release of encapsulated drug can be controlled. 
While commonly used to form nano- and microparticles for 
systemic drug delivery, PLG can also be fabricated into scaffolds 
for depot-based drug delivery. One important considerations for 
use of PLG scaffolds is that the rate of degradation and associated 
drug release is dependent on many factors (lactide/glycolide ratio, 
polymer molecular weight, degree of crystallinity, glass transition 
temperature, etc.) and can be difficult to predict (Makadia and 
Siegel, 2011). Additionally, degradation of PLG scaffolds releases 
lactic and glycolic acid, which can accelerate the rate of degradation 
and affect local tissue pH, potentially damaging nearby tissue (Liu 
et al., 2006). Select examples of scaffolds used for controlled drug 
delivery are listed in Table 4.
For pro-angiogenic applications, PLG scaffolds have been 
developed using a high-pressure carbon dioxide/salt leaching 
method where the delivery of VEGF is controlled by the rate of 
scaffold degradation (Figure 2F). Sustained VEGF delivery over 
~1 month was achieved, with the PLG–VEGF scaffold significantly 
increasing reperfusion of, and capillary density within, ischemic 
murine hindlimb as compared to empty scaffolds (Sun et al., 2005). 
In an attempt to mimic the temporal growth factor expression 
occurring in healthy tissue (Figure 1), PLG scaffolds were formed 
releasing VEGF followed by PDGF. In layer 1, PDGF was pre-
encapsulated in PLG microspheres and mixed with VEGF prior 
to scaffold formation, while layer 2 only contained VEGF. This 
resulted in spatially patterned scaffolds that provided delayed 
release of PDGF compared to VEGF. These dual-delivery scaf-
folds induced the formation of more, larger vessels than empty 
PLG scaffolds. However, due to the spatial patterning of the two 
layers, local protein delivery to the tissue was dependent on scaffold 
orientation during implantation (Mooney et al., 2007).
Alternately, by forming PLG scaffolds with microspheres 
already containing PDGF, which are subsequently mixed with 
VEGF, sustained release of both factors was achieved, with VEGF 
being released more rapidly than PDGF. Similar to the system 
just discussed, this biomaterial attempts to mimic the native pro-
angiogenic signaling cascade (Figure 1); however, this system has 
the advantage of spatial uniformity, causing temporal protein deliv-
ery to be independent of scaffold orientation. This dual-growth 
factor delivery system increased vessel density within the scaffold 
after subcutaneous implantation compared to scaffolds delivering 
either factor alone. Dual factor delivery also increased vessel size 
and maturity as compared to blank scaffolds or scaffolds releasing 
VEGF or PDGF alone (Richardson et al., 2001). This biomaterials 
strategy has also been used to temporally control the delivery of 
multiple pro-angiogenic (VEGF and Ang2) and pro-maturation 
(PDGF and Ang1) factors from a single scaffold. Scaffolds deliver-
ing all four growth factors over time courses motivated by healthy 
angiogenic signaling (Figure 1) and in vitro testing resulted in the 
formation of more mature vessels than controls and the formation 
of the largest vessels of any group investigated (Brudno et al., 2013). 
These PLG scaffold systems could easily be adapted for controlled 
delivery of peptide drugs, as the drugs (protein or peptide) are 
released upon degradation of the biomaterial and do not rely on 
size-hindered diffusion through the material (Figure 2F). Similar 
to the results showing improved vascularization upon co-delivery 
of VEGF and PDGF, PLG scaffolds could be developed that deliver 
Qk (the VEGF mimic) followed by PAB2-1c (the PDGF mimic) 
or T7 (Ang1 mimic).
engineering Successful Pro-Angiogenic 
Biomaterials
While a number of pro-angiogenic biomaterials have been dis-
cussed here, they are not equally well-suited to all pro-angiogenic 
therapeutic applications. All materials meet the over-arching 
requirement of biocompatibility, but the different environments 
and demands of ischemic peripheral tissue, ischemic cardiac 
tissue, diabetic ulcers, and tissue engineering applications result 
in vastly different material requirements. Ischemic cardiac tissue, 
for example, is most likely to be successfully treated by injectable 
materials that can be delivered laparoscopically, to provide initial 
structural support to the damaged heart, produce extended growth 
factor release, and eventually degrade (Chen et al., 2008). These 
design requirements makes the alginate, fibrin, ECM-based, enzy-
matically degradable PEG, and PEG-dextran gels discussed here 
very promising for cardiac applications, as they can be crosslinked 
in situ, either using a dual barrel syringe or UV-initiated photopo-
lymerizations. For all materials, testing would be required to ensure 
in  situ polymerization produces gels that provide similar drug 
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release and vascularization as ex situ polymerization, to address 
potential differences in crosslinking efficiency and drug encap-
sulation that could occur. The pH and temperature-responsive 
p(NIPAAm-co-PAA-co-BA) hydrogels have the added benefit of 
being crosslinked by the native tissue environment, thus avoiding 
the need for external stimuli for gelation (Garbern et al., 2010; 
Murry et al., 2011). Ischemic peripheral tissue has similar design 
requirements as cardiac applications and would likely be best 
treated by the same types of materials as cardiac tissue. While the 
use of biomaterials for cardiac regeneration has largely focused 
on delivery of pro-angiogenic proteins, multiple pro-angiogenic 
peptides could instead be delivered to ischemic cardiac tissue, 
such as Qk, AcSDKP, and T7, all of which have shown promising 
results in other in  vivo models (Liu et  al., 2003; Santulli et  al., 
2009; Slyke, 2011).
Diabetic wounds are readily accessible, and therefore do not 
require in  situ gel formation or degradation, as the biomaterial 
can simply be placed on the wound and removed after delivering 
its payload. Therefore, these ulcers could be treated by a wider 
range of materials, including the gelatin and PEtU-PDMS materi-
als discussed here. Diabetic ulcers are associated with myriad 
deficiencies beyond insufficient angiogenesis (Lobmann et  al., 
2002; Lerman et al., 2003; Galiano et al., 2004), and as such, would 
likely benefit from delivery of multiple protein or peptide drugs, 
or drugs that have more broad effects, such as GHK-containing 
peptides (Pickart, 2008). Additionally, some of the pro-angiogenic 
peptides discussed here have already been shown efficacious in 
treating diabetic wounds, such as T7 and GHK, making them even 
more attractive candidates for incorporation into biomaterials for 
treatment of these wounds (Pickart, 2008; Van Slyke et al., 2009). As 
PLG scaffolds must be formed externally and then implanted, they 
could also be used for diabetic ulcer treatment, but are not ideal 
for cardiac applications. However, these scaffolds present a unique 
material compared to the other gels discussed here, in that they have 
significantly greater structural integrity (Makadia and Siegel, 2011). 
This makes them the most attractive biomaterial discussed here for 
engineering tissues, such as bone, while softer gels are better suited 
for engineering more compliant tissues, such as kidney and liver. 
However, as previously discussed, the acidic environment caused 
by degradation of the PLG scaffolds can negatively affect tissue, and 
must be considered when using these biomaterials (Liu et al., 2006).
Concluding Remarks
From natural to synthetic, diffusion controlled to stimuli-
responsive, a number of biomaterials delivery systems have been 
developed to deliver pro-angiogenic factors, each presenting 
unique advantages and disadvantages. Building off seminal 
research, current research is producing more complex and intricate 
materials delivering pro-angiogenic drugs, inducing robust pro-
angiogenic effects in vivo. Delivery of multiple factors, with tight 
temporal control over factor release has been shown to induce 
formation of more mature vasculature than delivery of a single 
factor. Similarly, materials delivering pro-angiogenic factors in 
response to enzyme expression present a promising means to 
deliver drugs based on local tissue demands. While current research 
focuses largely on delivery of pro-angiogenic proteins, we feel 
that delivery of peptide drugs that mimic the bioactivity of these 
proteins presents a unique opportunity to develop novel, potent 
pro-angiogenic therapies. Additionally, materials combining many 
of the promising techniques already developed could present even 
more potent methods to induce therapeutic angiogenesis, such as 
temporally controlling stimuli-responsive release, or delivery of 
multiple factors in a stimuli-responsive manner.
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